secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000950170-23-010589
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics reports FY2022 net loss of $12.2M; positive ALS data for COYA 302
--------------------------------------------------------------------------------

- Net loss of $12.2M for FY2022 vs $4.9M in FY2021; R&D expense rose to $4.4M from $2.5M.
- Cash and cash equivalents $5.9M at Dec 31, 2022; IPO net proceeds of $14.5M received in Jan 2023.
- Positive proof-of-concept data for COYA 302 in ALS: halted disease progression over 6 months in 4 patients.
- Entered worldwide agreement with Dr. Reddy's to in-license abatacept biosimilar and out-license COYA 301.
- Anticipates IND filing for COYA 301 in FTD and COYA 302 in neurodegenerative diseases in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/0000950170-23-010589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/coya-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer